RESUMEN
Objective To investigate the impact of anemia and chronic kidney disease(CKD)on the prognosis of elderly patients with HFpEF.Methods A retrospective cohort study was conducted on 224 very old patients(age ≥80 years)with HFpEF admitted to Department of General Medi-cine of No.960 Hospital of PLA Joint Logistics Support Force from January 2016 to March 2023.According to their estimated glomerular filtration rate(eGFR)and hemoglobin level at admis-sion,they were divided into non-CKD+non-anemia group(88 cases),CKD group(14 cases),ane-mia group(79 cases)and CKD+anemic group(43 cases).The patients in the anemic group were further divided into mild(67 cases)and moderate-to-severe anemia subgroups(12 cases),and those of the CKD+anemia group were divided into CKD+mild anemia subgroup(31 cases)and CKD+moderate anemia subgroup(12 cases).The endpoints of follow-up included all-cause death,cardiovascular death and the end of follow-up.The relationships of CKD and anemia with progno-sis in elderly HFpEF patients were analyzed.Results During the follow-up period,all-cause mor-tality occurred in 100 patients(44.6％)and cardiovascular death in 32 patients(14.3％).Kaplan-Meier survival curve analysis showed that the CKD+anemia group had significantly higher rates of all-cause and cardiovascular death than the non-CKD+non-anemia,CKD and anemia groups(P＜0.01).Cox regression analysis indicated that the risk of all-cause mortality and cardiovascu-lar mortality was significantly higher in the CKD+moderate anemia subgroup than the non-CKD+non-anemia group(HR=6.43,95％CI:2.82-14.68,P=0.000;HR=10.63,95％CI:2.17-51.95,P=0.004).The risk of cardiovascular death was obviously higher in the moderate-to-severe anemia subgroup than in the non-CKD+non-anemia group(HR=4.96,95％CI:1.19-20.72,P=0.028).Conclusion Moderate-to-severe anemia is an independent risk factor for cardiovascular death in elderly HFpEF patients,and CKD complicated with moderate anemia significantly increa-ses the risk of all-cause mortality and cardiovascular death in elderly HFpEF patients.
RESUMEN
OBJECTIVE:To optimize the inclusion technology of Eugenol-β-cyclodextrin (β-CD) inclusion complex,and to identify and characterize it. METHODS:With the molar ratio of eugenol to β-CD,inclusion temperature and inclusion time as fac-tors,using the yield of inclusion compounds as index,the inclusion technology was optimized by orthogonal test. The formation of inclusion compound was identified by the spectra change of FT-IR,XRD and 1H NMR. Its structure was characterized by 1H RO-ESY NMR. RESULTS:The optimized inclusion conditions were that the molar ratio of eugenol to β-CD was 1.0:1;inclusion tem-perature was 60 ℃;inclusion time was 2.0 h. And the yield of inclusion compound was 73.86%(RSD=0.17%,n=3). 1H NMR results ofβ-CD and its inclusion complex indicated that the optimum qualitative ratio of the inclusion complex was 1.0:1. The inter-molecular interaction between eugenol and β-CD was confirmed by the spectrum analysis of FT-IR and XRD. 1H ROESY NMR re-sults indicated the structure of inclusion complex mainly was that the phenyl of eugenol was in the cavity of β-CD,the vinyl was outside. CONCLUSIONS:The inclusion technology is reasonable and feasible,and can be used for the inclusion of eugenol andβ-CD. The formation of inclusion compound is confirmed by the spectrum analysis.